Literature DB >> 25217522

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.

Chiara Ambrogio1, Francisco J Carmona2, August Vidal3, Mattia Falcone4, Patricia Nieto1, Octavio A Romero2, Sara Puertas5, Miguel Vizoso5, Ernest Nadal6, Teresa Poggio7, Montserrat Sánchez-Céspedes2, Manel Esteller8, Francisca Mulero9, Claudia Voena7, Roberto Chiarle10, Mariano Barbacid1, David Santamaría11, Alberto Villanueva12.   

Abstract

Cancer evolution is a process that is still poorly understood because of the lack of versatile in vivo longitudinal studies. By generating murine non-small cell lung cancer (NSCLC) orthoallobanks and paired primary cell lines, we provide a detailed description of an in vivo, time-dependent cancer malignization process. We identify the acquisition of metastatic dissemination potential, the selection of co-driver mutations, and the appearance of naturally occurring intratumor heterogeneity, thus recapitulating the stochastic nature of human cancer development. This approach combines the robustness of genetically engineered cancer models with the flexibility of allograft methodology. We have applied this tool for the preclinical evaluation of therapeutic approaches. This system can be implemented to improve the design of future treatments for patients with NSCLC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25217522     DOI: 10.1158/0008-5472.CAN-14-1606

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Authors:  Ester Bonastre; Sara Verdura; Ilse Zondervan; Federica Facchinetti; Sylvie Lantuejoul; Maria Dolores Chiara; Juan Pablo Rodrigo; Julian Carretero; Enric Condom; Agustin Vidal; David Sidransky; Alberto Villanueva; Luca Roz; Elisabeth Brambilla; Suvi Savola; Montse Sanchez-Cespedes
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

2.  In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.

Authors:  C Ambrogio; M Barbacid; D Santamaría
Journal:  Oncogene       Date:  2016-10-24       Impact factor: 9.867

3.  Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Authors:  Chiara Ambrogio; Gonzalo Gómez-López; Mattia Falcone; August Vidal; Ernest Nadal; Nicola Crosetto; Rafael B Blasco; Pablo J Fernández-Marcos; Montserrat Sánchez-Céspedes; Xiaomei Ren; Zhen Wang; Ke Ding; Manuel Hidalgo; Manuel Serrano; Alberto Villanueva; David Santamaría; Mariano Barbacid
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

4.  Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.

Authors:  Marie-Julie Nokin; Elodie Darbo; Camille Travert; Benjamin Drogat; Aurélie Lacouture; Sonia San José; Nuria Cabrera; Béatrice Turcq; Valérie Prouzet-Mauleon; Mattia Falcone; Alberto Villanueva; Haiyun Wang; Michael Herfs; Miguel Mosteiro; Pasi A Jänne; Jean-Louis Pujol; Antonio Maraver; Mariano Barbacid; Ernest Nadal; David Santamaría; Chiara Ambrogio
Journal:  JCI Insight       Date:  2020-08-06

5.  Requirement for epithelial p38α in KRAS-driven lung tumor progression.

Authors:  Jessica Vitos-Faleato; Sebastián M Real; Nuria Gutierrez-Prat; Alberto Villanueva; Elisabet Llonch; Matthias Drosten; Mariano Barbacid; Angel R Nebreda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-22       Impact factor: 11.205

6.  Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.

Authors:  Elisabet Aliagas; Ania Alay; Maria Martínez-Iniesta; Miguel Hernández-Madrigal; David Cordero; Mireia Gausachs; Eva Pros; Maria Saigí; Sara Busacca; Annabel J Sharkley; Alan Dawson; Ramón Palmero; José C Ruffinelli; Susana Padrones; Samantha Aso; Ignacio Escobar; Ricard Ramos; Roger Llatjós; August Vidal; Eduard Dorca; Mar Varela; Montse Sánchez-Céspedes; Dean Fennell; Cristina Muñoz-Pinedo; Alberto Villanueva; Xavi Solé; Ernest Nadal
Journal:  Br J Cancer       Date:  2021-09-29       Impact factor: 9.075

7.  ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.

Authors:  Yutong Zhao; Jiaqi Li; Jens Köhler; Prafulla C Gokhale; Hong L Tiv; Aine R Knott; Margaret K Wilkens; Kara M Soroko; Mika Lin; Chiara Ambrogio; Monica Musteanu; Atsuko Ogino; Jihyun Choi; Magda Bahcall; Arrien A Bertram; Emily S Chambers; Cloud P Paweletz; Shripad V Bhagwat; Jason R Manro; Ramon V Tiu; Pasi A Jänne
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

8.  Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

Authors:  María García-Beccaria; Paula Martínez; Marinela Méndez-Pertuz; Sonia Martínez; Carmen Blanco-Aparicio; Marta Cañamero; Francisca Mulero; Chiara Ambrogio; Juana M Flores; Diego Megias; Mariano Barbacid; Joaquín Pastor; Maria A Blasco
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

9.  Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Authors:  Matteo Menotti; Cristina Mastini; Claudia Voena; Filomena Di Giacomo; Dario Livio Longo; Barbara Castella; Maria Elena Boggio Merlo; Chiara Ambrogio; Qi Wang; Valerio Giacomo Minero; Teresa Poggio; Cinzia Martinengo; Lucia D'Amico; Elena Panizza; Luca Mologni; Federica Cavallo; Fiorella Altruda; Mohit Butaney; Marzia Capelletti; Giorgio Inghirami; Pasi A Jänne; Roberto Chiarle
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151

Review 10.  Tumour Cell Heterogeneity.

Authors:  Laura Gay; Ann-Marie Baker; Trevor A Graham
Journal:  F1000Res       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.